Colossal bets de-extinction is the demo, gene tools are the business; $10.2B and rising

Genetics company engineering 'de-extinction' of the woolly mammoth, dodo and Tasmanian tiger (plus dire wolf) while spinning out tools: Form Bio, Breaking, Astromech.

Build gene-editing and computational biology for de-extinction, sell to governments and biotech; the mammoth only buys headlines.

Ben Lamm, a Dallas serial entrepreneur, co-founded Colossal in 2021 with the grand pitch of resurrecting the woolly mammoth by 2028. The method: sequence the extinct genome completely, compare it with the closest living relative (the Asian elephant), edit living cells with CRISPR and gestate embryos in a surrogate. Investors valued the editing tech over the spectacle — a reported ~$1.5B round closed in early 2023, two years before the company would even claim revenue.

January 2025: a $200M Series C at a $10.2B valuation from TWG Global (Guggenheim partner Mark Walter and billionaire Thomas Tull) — two years after the prior round's reported $1.5B mark — with Lamm telling TechCrunch investors were paying for the speed of technology creation, not revenue. March 2025: the 'woolly mouse,' CRISPR-edited mice carrying mammoth fur genes, born healthy from surrogate mothers; Lamm called it a watershed moment. April 2025: dire wolves — gray wolf cells edited with 20 genes governing appearance, implanted into a large domestic dog, producing pups Remus, Romulus and Khaleesi. UC Davis and UCLA scientists objected that it was a modified gray wolf rather than de-extinction; George R.R. Martin joined as adviser; Colossal paired the project with red-wolf conservation. In late April 2026 it added the bluebuck antelope as a sixth species.

Privately held and pre-profit: revenue began flowing only in the last year (Axios, via TechCrunch, Jul 2026). Flagship projects — woolly mammoth and Tasmanian tiger — still target 2028, while the investor story has shifted from resurrection to the tools that resurrection forced them to build.

PR-gravity species converted lab progress into global news, keeping investors engaged without marketing budget.

Selling the stack gave skeptics a reason to pay: even critics agreed the genome-editing pipeline was valuable.

Spinouts turned R&D byproducts into financed companies, creating valuation milestones while parent stayed pre-revenue.

Government and UAE money came early, de-risking a company whose product was 2028.

The public 2028 deadline drives velocity but risks headlines against it if missed.

Sell the moonshot, monetize the enabling tech: flagship species buy attention while tools compound into the business. Keep the public deadline; missed dates cost the story.

As of Sep 2, 2026, Colossal is privately held, Dallas-based, pre-profit, and in talks to raise at $20B-$30B (Axios via TechCrunch, Jul 20, 2026). Revenue began, including $60M from UAE. Spinouts Form Bio ($30M), Breaking, and Astromech (~$2B) carry commercial weight. Species grew to six with bluebuck (Apr 2026); dire wolves past 120 lb (May 2026). Artificial womb could be ready 2027. Mammoth and tiger target 2028.